WGS
HealthcareGeneDx Holdings Corp. · Medical - Healthcare Information Services · $1B
What is GeneDx Holdings Corp.?
GeneDx Holdings Corp. is a health intelligence company applying AI and machine learning to genomic and clinical data to help define individualized health trajectories for patients.
The company operates the Centrellis health intelligence platform, which combines multidimensional clinical and genomic data to generate deeper understanding of disease and wellness. GeneDx monetizes this through science-driven diagnostic and health intelligence solutions aimed at addressing complex, unmet medical needs across the healthcare system.
GeneDx Holdings is headquartered in Stamford, CT, with roots tracing to 2015.
- Centrellis health intelligence platform
- AI-driven genomic analysis
- Longitudinal clinical data modeling
- Individualized health trajectory solutions
Is WGS a Good Stock to Buy?
UQS Score rates WGS as Below Average overall.
GeneDx's standout characteristic is its Growth pillar, rated Strong — reflecting meaningful revenue expansion in a rapidly evolving genomics market. The Moat pillar registers as Neutral, suggesting some differentiation through its proprietary platform.
Quality and Risk both rate Weak, pointing to profitability challenges and elevated financial uncertainty. Valuation is rated Elevated, meaning the market already prices in considerable optimism.
See the exact pillar breakdown and full financial metrics by signing up for a Pro membership at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does WGS pay dividends?
No — GeneDx Holdings Corp. does not currently pay a dividend.
GeneDx does not currently pay a dividend. As an early-stage health intelligence company focused on platform development and growth, capital is directed toward R&D and expanding its genomic data capabilities rather than shareholder distributions.
When does WGS report earnings?
GeneDx reports earnings on a quarterly cadence, typical for US-listed equities.
The company has demonstrated meaningful top-line growth, consistent with its Strong Growth pillar rating. However, profitability remains a work in progress, which is reflected in the Weak Quality and Risk ratings.
For the most recent quarter's results, visit GeneDx Holdings' investor relations page directly.
WGS Price History
-83.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in GeneDx Holdings Corp.?
Based on GeneDx Holdings Corp.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does GeneDx do?
GeneDx is a health intelligence company that uses AI and machine learning to analyze genomic and clinical data. Its Centrellis platform helps build dynamic models of human health, aiming to deliver personalized, science-driven solutions to complex medical challenges.
Does WGS pay dividends?
No, WGS does not pay a dividend. GeneDx is focused on reinvesting resources into its platform and growth initiatives, which is common for early-stage healthcare technology companies.
When does WGS report earnings?
GeneDx reports on a standard quarterly schedule. For exact dates and the most recent results, check the investor relations section of the GeneDx Holdings website.
Is WGS a good stock to buy?
WGS carries a Below Average UQS Score. Its Strong Growth pillar is a positive signal, but Weak Quality and Risk ratings alongside an Elevated Valuation suggest meaningful uncertainty. Reviewing the full pillar breakdown on UQS Score can help inform your decision.
Is WGS overvalued?
The UQS Valuation pillar for WGS is rated Elevated, indicating the current market price reflects high expectations relative to the company's fundamentals. This is worth weighing against the Strong Growth profile.
What is WGS's market cap bracket?
GeneDx Holdings is classified as a small-cap company, meaning it carries a relatively modest market capitalization compared to large or mega-cap peers in the healthcare sector.
Is WGS a long-term quality indicator?
From a long-term quality perspective, WGS shows a mixed profile. Strong Growth is encouraging, but Weak Quality and Risk ratings highlight execution and financial stability risks that long-term investors should monitor closely.
What sector does WGS belong to?
GeneDx operates in the Healthcare sector, specifically at the intersection of genomics, AI-driven diagnostics, and health intelligence — a high-growth but competitive and capital-intensive segment.
Unlock Full WGS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete pillar-by-pillar score breakdown for WGS
- ✓Access detailed financial metrics behind each rating
- ✓Compare WGS against sector peers on every pillar
- ✓Get the full analyst-grade quality view available to Pro members
Pro Analysis
WGS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | 44.6 | 0.0 | 42.0 | 95.4 | 36.9 | 63.4 | -1.8 |
| May 7, 2026 | 46.4 | 18.2 | 42.0 | 95.4 | 39.3 | 42.3 | +1.2 |
| May 3, 2026 | 45.2 | 18.2 | 42.0 | 95.4 | 39.3 | 34.2 | +0.1 |
| Apr 26, 2026 | 45.1 | 18.2 | 42.0 | 95.4 | 39.3 | 33.8 | 0.0 |
| Apr 19, 2026 | 45.1 | 18.2 | 42.0 | 95.4 | 39.3 | 34.1 | -0.2 |
| Apr 18, 2026 | 45.3 | 18.2 | 42.0 | 95.4 | 39.3 | 35.0 | -1.3 |
| Apr 12, 2026 | 46.6 | 18.2 | 42.0 | 95.4 | 39.3 | 43.8 | +0.2 |
| Apr 5, 2026 | 46.4 | 18.2 | 42.0 | 95.4 | 39.3 | 42.6 | 0.0 |
| Apr 2, 2026 | 46.4 | 18.2 | 42.0 | 95.4 | 39.3 | 42.7 | — |
WGS — Pillar Breakdown
Quality
— 16.7/100 (25%)GeneDx Holdings Corp. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 95.4/100 (20%)GeneDx Holdings Corp. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 77.4/100 (15%)GeneDx Holdings Corp. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 41.0/100 (15%)GeneDx Holdings Corp. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 42/100 (25%)GeneDx Holdings Corp. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for WGS.
Score Composition
Financial Data
More Stock Analysis
How is the WGS UQS Score Calculated?
The UQS (Unified Quality Score) for GeneDx Holdings Corp. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses GeneDx Holdings Corp.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether GeneDx Holdings Corp. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.